146 related articles for article (PubMed ID: 8540355)
1. Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine.
Baldwin ET; Bhat TN; Gulnik S; Liu B; Kiso Y; Mitsuya H; Erickson JW
Adv Exp Med Biol; 1995; 362():445-9. PubMed ID: 8540355
[No Abstract] [Full Text] [Related]
2. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
Kiso Y
Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
[No Abstract] [Full Text] [Related]
4. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
Kiso Y
Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
[TBL] [Abstract][Full Text] [Related]
6. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography.
Adachi M; Ohhara T; Kurihara K; Tamada T; Honjo E; Okazaki N; Arai S; Shoyama Y; Kimura K; Matsumura H; Sugiyama S; Adachi H; Takano K; Mori Y; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Kuroki R
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4641-6. PubMed ID: 19273847
[TBL] [Abstract][Full Text] [Related]
7. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
[TBL] [Abstract][Full Text] [Related]
8. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
9. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.
Mimoto T; Imai J; Tanaka S; Hattori N; Kisanuki S; Akaji K; Kiso Y
Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):3088-90. PubMed ID: 1799953
[TBL] [Abstract][Full Text] [Related]
10. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
[TBL] [Abstract][Full Text] [Related]
11. [Kynostatin (KNI)-272--a rationally designed tripeptide inhibitor of HIV protease].
Kiso Y
Nihon Rinsho; 1993 Sep; 51 Suppl():139-45. PubMed ID: 8271377
[No Abstract] [Full Text] [Related]
12. Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 A structure.
Reiling KK; Endres NF; Dauber DS; Craik CS; Stroud RM
Biochemistry; 2002 Apr; 41(14):4582-94. PubMed ID: 11926820
[TBL] [Abstract][Full Text] [Related]
13. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
14. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
Smith AB; Hirschmann R; Pasternak A; Yao W; Sprengeler PA; Holloway MK; Kuo LC; Chen Z; Darke PL; Schleif WA
J Med Chem; 1997 Aug; 40(16):2440-4. PubMed ID: 9258349
[No Abstract] [Full Text] [Related]
15. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
Kempf DJ
Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
[No Abstract] [Full Text] [Related]
16. Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
Hidaka K; Kimura T; Sankaranarayanan R; Wang J; McDaniel KF; Kempf DJ; Kameoka M; Adachi M; Kuroki R; Nguyen JT; Hayashi Y; Kiso Y
J Med Chem; 2018 Jun; 61(12):5138-5153. PubMed ID: 29852069
[TBL] [Abstract][Full Text] [Related]
17. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
McCarrick MA; Kollman P
Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
[No Abstract] [Full Text] [Related]
18. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
Lu Y; Yang CY; Wang S
J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
[TBL] [Abstract][Full Text] [Related]
19. Solution conformations of KNI-272, a tripeptide HIV protease inhibitor designed on the basis of substrate transition state: determined by NMR spectroscopy and simulated annealing calculations.
Ohno Y; Kiso Y; Kobayashi Y
Bioorg Med Chem; 1996 Sep; 4(9):1565-72. PubMed ID: 8894113
[TBL] [Abstract][Full Text] [Related]
20. The importance of being floppy.
Wagner G
Nat Struct Biol; 1995 Apr; 2(4):255-7. PubMed ID: 7796257
[No Abstract] [Full Text] [Related]
[Next] [New Search]
